Population Pharmacokinetics of Anti-infectious Drugs in Children (PHARMA-A)
The Pharm A project is a French national collaborative project aiming to determine the population pharmacokinetics of ceftazidime, ciprofloxacin, and voriconazole in paediatric patients aged one month to five years.
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Population Pharmacokinetics Of Ceftazidime, Ciprofloxacin And Voriconazole In Paediatric Young Patients (< 12 Years Old)|
- Population pharmacokinetic parameters and factors explaining variability [ Time Frame: Between 2 and 4 days after the begining of the treatment ] [ Designated as safety issue: No ]
Population Pharmacokinetic Parameters and variability factors (Sex, Age, Genetic factors...) for ceftazidime, ciprofloxacin and voriconazole.
According to the age of participants, 2 or 3 bloods sampling will be take between 2 and 4 days after the beginning of the treatment.
- Covariability factors explaining the variability (age, biological data, pharmacokinetics factors, associated treatments...) [ Time Frame: Between 2 and 4 days after the beginning of the treatment ] [ Designated as safety issue: No ]
|Study Start Date:||June 2011|
|Estimated Study Completion Date:||June 2014|
|Estimated Primary Completion Date:||June 2014 (Final data collection date for primary outcome measure)|
|Experimental: Patients treated with Ceftazidime||
Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.
|Experimental: Patients treated with Ciprofloxacin||
Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.
|Experimental: Patients treated with Voriconazole||
Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.
The licensing process was introduced in order to ensure that medicines are safe, effective and of high quality. However, over 50% of children admitted to hospital in France and Europe will receive an unlicensed or off-label medicine. This occurs for most drugs in children less than 6 years of age. They represent a particularly vulnerable subgroup of the paediatric population.
There are major practical and ethical issues in relation to studying medicines in paediatric patients aged 5 years or less.
- They represent only a small part of the population as compared to older children and adults, and the variation of specific types of diseases in this young subpopulation is higher than in the paediatric counterpart. There are major differences in drug disposition in the different age groups.
- There is a need for suitable methodological approaches for clinical trials
- There are major ethical issues It is essential, therefore, to recruit children from various regions in France in order to obtain a critical sample size of sufficient magnitude and to conduct scientific sound studies. This will be achieved by performing Pharm A, a population pharmacokinetic study of three different anti infectious agents (ceftazidime, ciprofloxacin, voriconazole) and identify covariates including pharmacogenetic biomarkers that explain pharmacokinetic variability.
After parental informed consent, sampling strategy will be randomized depending on the drug and the age group (2 samples in patients below 2 years and 3 samples in patients from 2 to 5 years).
|Contact: Stéphanie Bui, Dr||(33) 5 56 79 87 firstname.lastname@example.org|
|Contact: Michael Fayon, Pr||(33) 5 56 79 98 24||Michael.email@example.com|
|CHU de Bordeaux, Hôpital Pellegrin||Recruiting|
|Bordeaux, France, 33076|
|Contact: Stéphanie BUI, Dr (33) 5 56 79 87 37 firstname.lastname@example.org|
|Principal Investigator: Stéphanie BUI, Dr|
|Sub-Investigator: Michael FAYON, Pr|
|Sub-Investigator: Cécile VERITE, Dr|
|Sub-Investigator: Paul NOLENT, Dr|
|Hospices Civils de Lyon||Recruiting|
|Bron, France, 69500|
|Contact: Yves BERTRAND, Pr email@example.com|
|Principal Investigator: Yves BERTRAND, Pr|
|CHU Clermont Ferrand||Recruiting|
|Clermont Ferrand, France, 63000|
|Contact: François Demeocq, Pr firstname.lastname@example.org|
|Principal Investigator: François Demeocq, Pr|
|CHU de Dijon||Recruiting|
|Dijon, France, 21079|
|Contact: Marc BARDOU marc.Bardou@u-bourgogne.fr|
|Principal Investigator: Marc BARDOU, Pr|
|Sub-Investigator: Frédéric HUET, Pr|
|CHU de Grenoble||Recruiting|
|Grenoble, France, 38043|
|Contact: Isabelle PIN, Dr|
|Principal Investigator: Isabelle PIN, Dr|
|Lille, France, 59037|
|Contact: Frédéric Gottrand, Pr|
|Principal Investigator: Frédéric GOTTRAND, Pr|
|AP-HM, Hôpital La Timone||Recruiting|
|Marseille, France, 13005|
|Contact: Michel Tsimaratos, Pr|
|Principal Investigator: Michel Tsimaratos, Pr|
|Montpellier, France, 34925|
|Contact: Gilles Cambonie, Pr email@example.com|
|Principal Investigator: Gilles CAMBONIE, Pr|
|APHP - Hôpital NEcker||Recruiting|
|Paris, France, 75015|
|Contact: Jean-Marc Treluyer, Pr|
|Principal Investigator: Jean-Marc Treluyer, Pr|
|AP-HP - Hôpital Robert Debré||Recruiting|
|Paris, France, 75019|
|Contact: Evelyne Jacz-Aigrain, Pr firstname.lastname@example.org|
|Principal Investigator: Evelyne Jacz-Aigrain, Pr|
|Poitiers, France, 86000|
|Contact: Régis Hankard, Dr email@example.com|
|Principal Investigator: Régis HANKARD, Dr|
|Rouen, France, 76031|
|Contact: Eric MALLET firstname.lastname@example.org|
|Principal Investigator: Eric MALLET, Pr|
|Toulouse, France, 31059|
|Contact: Jean-Pierre SALLES, Pr email@example.com|
|Principal Investigator: Jean-Pierre SALLES, Pr|
|Tours, France, 37044|
|Contact: François Labarthe firstname.lastname@example.org|
|Principal Investigator: François LABARTHE, Pr|
|Principal Investigator:||Stéphanie Bui, Dr||University Hospital Bordeaux, France|